• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·ARTEMISMED.NS
Share

Artemis Medicare Services Limited Stocks

₹ 347.9Last Updated 10.09.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

₹ 557.06M

₹ 347.9
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Artemis Medicare Services Limited engages in the management and operation of multi-specialty hospitals in India and internationally. The company provides medical and surgical intervention, and inpatient and outpatient services. It also offers billing and insurance, childcare, emotional and support program, full body checkup, international patient, medical interpreter and record, mind body medicine, nursing, nutrition, patient and family advisory, patient advocacy and portal, pre-admission testing, and smoking cessation program services, as well as home care services. Artemis Medicare Services Limited was incorporated in 2004 and is based in Gurugram, India.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, over

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of ARTEMISMED.NS is 329 and suggests 7.02% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendat

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

10.09.2026 21:24

The owner of Vimeo has agreed to acquire Miro, a company with Russian roots, for $1.4 billion

10.09.2026 20:22

Europe's largest airline has warned of the risk of a "significant increase" in prices due to oil prices

10.09.2026 19:47

A Historic Shift: BlackRock Proposes an Alternative to the 60/40 Portfolio

10.09.2026 19:09

"A Bit of Chaos": How Sergey Brin Is Building Gemini in Startup Style in a Kitchen at Google

10.09.2026 18:40

The Nasdaq fell 1% at the start of trading in the U.S. due to a sharp rise in oil prices

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026